GTB-5550 is now the 3rd TriKE ® to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose escalation phase Company anticipates providing updates in 2H 2026 as enrollment progresses through dose escalation cohorts SAN FRANCISCO, CALIFORNIA, May 14, 2026 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary TriKE® natural killer (NK) cell engager platform, today announced that the first patient was dosed in a Phase 1 dose escalation basket trial evaluating GTB-5550, its B7-H3-targeted natural killer (NK) cell engager for solid tumors expressing B7-H3. “Dosing the first patient in our GTB-5550 Phase 1 trial is a pivotal milestone for GT Biopharma and represents the natural evolution of our TriKE® platform into the broader opportunity of treating patients with a variety of solid tumors.
This excerpt is quoted from the original release. Read the full announcement on GlobeNewsWire.
Brief Summary
GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company, has achieved a significant milestone by dosing the first patient in the Phase 1 clinical trial for GTB-5550, a novel B7-H3-targeted NK cell engager. This trial marks the third TriKE® to enter clinical evaluation and aims to expand treatment opportunities for patients with solid tumors, particularly focusing on prostate cancer in the initial dose escalation phase.
- First patient dosed in Phase 1 trial for GTB-5550.
- Targeting solid tumors expressing B7-H3.
- Trial aims to include prostate cancer patients during dose escalation.
- Updates expected in 2H 2026 as trial progresses.
Why it matters: This marks a pivotal advancement in GT Biopharma’s commitment to developing innovative immunotherapy solutions, which could significantly impact the treatment landscape for solid tumors.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by GlobeNewsWire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.
